Table 3.
Model 1a | Model 2b | |||||
---|---|---|---|---|---|---|
HRc | 95% CI | P value | HRc | 95% CI | P value | |
Local recurrence 62 events Total time at risk = 9,683 years |
1.99 | 1.09-3.66 | 0.026 | 1.92 | 1.03-3.57 | 0.039 |
Locoregional recurrence 103 events Total time at risk = 9,606 years |
1.84 | 1.16-2.91 | 0.010 | 1.67 | 1.04-2.69 | 0.033 |
Distant recurrence 181 events Total time at risk = 9,618 years |
1.28 | 0.90-1.82 | 0.170 | 1.08 | 0.74-1.56 | 0.698 |
5-year breast cancer-specific survival 124 events Total time at risk = 8,489 years |
1.25 | 0.82-1.92 | 0.299 | 0.97 | 0.61-1.54 | 0.908 |
10-year breast cancer-specific survival 213 events Total time at risk = 16,016 years |
1.34 | 0.97-1.85 | 0.080 | 1.08 | 0.77-1.53 | 0.644 |
Overall 5-year survival 174 events Total time at risk = 8,489 years |
1.07 | 0.73-1.55 | 0.742 | 0.89 | 0.60-1.32 | 0.554 |
Overall 10-year survival 358 events Total time at risk = 16,016 years |
1.14 | 0.87-1.48 | 0.343 | 0.99 | 0.75-1.29 | 0.921 |
aAdjusted for age, body mass index (BMI), and hormone replacement therapy (HRT) use;
badjusted for age, BMI, HRT use, mode of detection, tumor size, lymph node metastasis, estrogen receptor status, progesterone receptor status, and grade;
chazard ratio (HR) comparing percentage density (PD) ≥25% to PD <25%. CI, confidence interval.